Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA5A | P35218 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | GLA | P06280 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1725625 | 1.00 | CYP3A4 (0.44) | CYP3A4ACHEUSP2CA2CA5A | |
| SCHEMBL1724275 | 1.00 | CYP3A4 (0.44) | CYP3A4ACHEUSP2CA2CA5A | |
| SCHEMBL2070082 | 1.00 | CYP3A4 (0.44) | CYP3A4ACHEUSP2CA2CA5A | |
| SCHEMBL2070356 | 0.94 | CYP3A4 (0.46) | CYP3A4USP2MAPTTDP1MAPK1 | |
| SCHEMBL2070355 | 0.94 | CYP3A4 (0.46) | CYP3A4USP2MAPTTDP1MAPK1 | |
| SCHEMBL2070802 | 0.94 | CYP3A4 (0.46) | CYP3A4USP2MAPTTDP1MAPK1 | |
| SCHEMBL2070800 | 0.94 | CYP3A4 (0.46) | CYP3A4USP2MAPTTDP1MAPK1 | |
| SCHEMBL4427817 | 0.93 | CYP3A4 (0.41) | CYP3A4ACHEUSP2CA2CA5A | |
| SCHEMBL2069980 | 0.93 | CYP3A4 (0.45) | CYP3A4ACHEMAPTTDP1MAPK1 | |
| SCHEMBL2069977 | 0.93 | CYP3A4 (0.45) | CYP3A4ACHEMAPTTDP1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150240275-A1 | ENZYME ASSOCIATED WITH EQUOL SYNTHESIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-08-27 | — | — | US | disclosed |
| US-8993296-B2 | Enzyme associated with equol synthesis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-03-31 | — | — | US | disclosed |
| US-8993296-B2 | Enzyme associated with equol synthesis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-03-31 | — | — | US | disclosed |
| US-20140315264-A1 | ENZYME ASSOCIATED WITH EQUOL SYNTHESIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| US-20140315264-A1 | ENZYME ASSOCIATED WITH EQUOL SYNTHESIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| US-8669088-B2 | Enzyme associated with equol synthesis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-03-11 | — | — | US | disclosed |
| US-8669088-B2 | Enzyme associated with equol synthesis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-03-11 | — | — | US | disclosed |
| EP-2404995-B1 | Enzyme associated with equol synthesis | OTSUKA PHARMA CO LTD (JP) | 2013-07-17 | — | — | EP | disclosed |
| EP-2404994-B1 | Enzyme associated with equol synthesis | OTSUKA PHARMA CO LTD (JP) | 2013-07-03 | — | — | EP | disclosed |
| EP-2228441-B1 | ENZYME INVOLVED IN SYNTHESIS OF EQUOL | OTSUKA PHARMA CO LTD (JP) | 2013-06-19 | — | — | EP | disclosed |
| US-7906660-B2 | Production of isoflavone derivatives | NOVOGEN RESEARCH PTY LTD (AU) | 2011-03-15 | — | — | US | disclosed |
| US-20100330627-A1 | ENZYME ASSOCIATED WITH EQUOL SYNTHESIS | OTSUKA PHARMACEUTICAL CO. LTD. (JP) | 2010-12-30 | — | — | US | disclosed |
| US-20100330627-A1 | ENZYME ASSOCIATED WITH EQUOL SYNTHESIS | OTSUKA PHARMACEUTICAL CO. LTD. (JP) | 2010-12-30 | — | — | US | disclosed |
| EP-2228441-A1 | ENZYME INVOLVED IN SYNTHESIS OF EQUOL | Otsuka Pharmaceutical Co., Ltd. (JP) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009084603-A1 | ENZYME INVOLVED IN SYNTHESIS OF EQUOL | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-07-09 | — | — | WO | disclosed |
| US-20060217564-A1 | Production of isoflavone derivatives | NOVOGEN RESEARCH PTY LTD. | 2006-09-28 | — | — | US | disclosed |
| US-20050143588-A1 | Production of isoflavone derivatives | NOVOGEN RESEARCH PTY LTD. | 2005-06-30 | — | — | US | disclosed |
| EP-1153020-A4 | PRODUCTION OF ISOFLAVONE DERIVATIVES | NOVOGEN RES PTY LTD (AU) | 2002-08-21 | — | — | EP | disclosed |
| EP-1153020-A1 | PRODUCTION OF ISOFLAVONE DERIVATIVES | Novogen Research Pty. Ltd. (AU) | 2001-11-14 | — | — | EP | disclosed |
| WO-2000049009-A1 | PRODUCTION OF ISOFLAVONE DERIVATIVES | NOVOGEN RESEARCH PTY. LTD. (AU) | 2000-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217564-A1 | Production of isoflavone derivatives | CYP51A1, EGLN2, EGLN3 | CYP3A4 14/4885ACHE 3802/4885USP2 2930/4885 |
| US-20050143588-A1 | Production of isoflavone derivatives | CYP51A1, EGLN2, EGLN3 | CYP3A4 14/4885ACHE 3802/4885USP2 2930/4885 |
| US-20100330627-A1 | ENZYME ASSOCIATED WITH EQUOL SYNTHESIS | DHODH, DHPS, HPGD | CYP3A4 171/4885ACHE 1607/4885USP2 1462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.